ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $34.63 billion. The enterprise value is $33.98 billion.
| Market Cap | 34.63B |
| Enterprise Value | 33.98B |
Important Dates
The next confirmed earnings date is Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Aug 20, 2026 |
Share Statistics
ResMed has 140.64 million shares outstanding. The number of shares has decreased by -0.87% in one year.
| Current Share Class | 140.64M |
| Shares Outstanding | 140.64M |
| Shares Change (YoY) | -0.87% |
| Shares Change (QoQ) | -0.51% |
| Owned by Insiders (%) | 0.55% |
| Owned by Institutions (%) | 80.32% |
| Float | 139.73M |
Valuation Ratios
The trailing PE ratio is 23.60 and the forward PE ratio is 20.37. ResMed's PEG ratio is 1.51.
| PE Ratio | 23.60 |
| Forward PE | 20.37 |
| PS Ratio | 6.12 |
| Forward PS | 5.97 |
| PB Ratio | 5.39 |
| P/TBV Ratio | 10.74 |
| P/FCF Ratio | 20.99 |
| P/OCF Ratio | 19.17 |
| PEG Ratio | 1.51 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.21, with an EV/FCF ratio of 20.60.
| EV / Earnings | 22.31 |
| EV / Sales | 6.01 |
| EV / EBITDA | 16.21 |
| EV / EBIT | 17.70 |
| EV / FCF | 20.60 |
Financial Position
The company has a current ratio of 3.10, with a Debt / Equity ratio of 0.13.
| Current Ratio | 3.10 |
| Quick Ratio | 1.83 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.39 |
| Debt / FCF | 0.50 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 24.27% and return on invested capital (ROIC) is 26.23%.
| Return on Equity (ROE) | 24.27% |
| Return on Assets (ROA) | 14.00% |
| Return on Invested Capital (ROIC) | 26.23% |
| Return on Capital Employed (ROCE) | 25.36% |
| Weighted Average Cost of Capital (WACC) | 8.18% |
| Revenue Per Employee | $497,225 |
| Profits Per Employee | $133,975 |
| Employee Count | 11,370 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 2.23 |
Taxes
In the past 12 months, ResMed has paid $396.12 million in taxes.
| Income Tax | 396.12M |
| Effective Tax Rate | 20.64% |
Stock Price Statistics
The stock price has decreased by -9.29% in the last 52 weeks. The beta is 0.75, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -9.29% |
| 50-Day Moving Average | 228.47 |
| 200-Day Moving Average | 225.03 |
| Relative Strength Index (RSI) | 72.90 |
| Average Volume (20 Days) | 1,008,428 |
Short Selling Information
The latest short interest is 12.78 million, so 9.09% of the outstanding shares have been sold short.
| Short Interest | 12.78M |
| Short Previous Month | 13.07M |
| Short % of Shares Out | 9.09% |
| Short % of Float | 9.15% |
| Short Ratio (days to cover) | 10.02 |
Income Statement
In the last 12 months, ResMed had revenue of $5.65 billion and earned $1.52 billion in profits. Earnings per share was $10.43.
| Revenue | 5.65B |
| Gross Profit | 3.48B |
| Operating Income | 1.92B |
| Pretax Income | 1.92B |
| Net Income | 1.52B |
| EBITDA | 2.10B |
| EBIT | 1.92B |
| Earnings Per Share (EPS) | $10.43 |
Balance Sheet
The company has $1.47 billion in cash and $825.92 million in debt, with a net cash position of $643.32 million or $4.57 per share.
| Cash & Cash Equivalents | 1.47B |
| Total Debt | 825.92M |
| Net Cash | 643.32M |
| Net Cash Per Share | $4.57 |
| Equity (Book Value) | 6.59B |
| Book Value Per Share | 45.66 |
| Working Capital | 2.93B |
Cash Flow
In the last 12 months, operating cash flow was $1.81 billion and capital expenditures -$156.29 million, giving a free cash flow of $1.65 billion.
| Operating Cash Flow | 1.81B |
| Capital Expenditures | -156.29M |
| Depreciation & Amortization | 175.83M |
| Net Borrowing | -10.00M |
| Free Cash Flow | 1.65B |
| FCF Per Share | $11.73 |
Margins
Gross margin is 61.62%, with operating and profit margins of 33.96% and 26.94%.
| Gross Margin | 61.62% |
| Operating Margin | 33.96% |
| Pretax Margin | 33.95% |
| Profit Margin | 26.94% |
| EBITDA Margin | 37.07% |
| EBIT Margin | 33.96% |
| FCF Margin | 29.18% |
Dividends & Yields
This stock pays an annual dividend of $2.64, which amounts to a dividend yield of 1.07%.
| Dividend Per Share | $2.64 |
| Dividend Yield | 1.07% |
| Dividend Growth (YoY) | 12.33% |
| Years of Dividend Growth | 13 |
| Payout Ratio | 25.31% |
| FCF Payout Ratio | 22.51% |
| Buyback Yield | 0.87% |
| Shareholder Yield | 1.95% |
| Earnings Yield | 4.24% |
| FCF Yield | 4.76% |
Analyst Forecast
The average price target for ResMed is $251.99, which is 2.35% higher than the current price. The consensus rating is "Buy".
| Price Target | $251.99 |
| Price Target Difference | 2.35% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 5.37% |
| EPS Growth Forecast (3Y) | 8.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 11.92 and a Piotroski F-Score of 6.
| Altman Z-Score | 11.92 |
| Piotroski F-Score | 6 |